Identification of the Ghrelin and Cannabinoid CB2 Receptor Heteromer Functionality and Marked Upregulation in Striatal Neurons from Offspring of Mice under a High-Fat Diet

Cannabinoids have been reported as orexigenic, i.e., as promoting food intake that, among others, is controlled by the so-called “hunger” hormone, ghrelin. The aim of this paper was to look for functional and/or molecular interactions between ghrelin GHSR1a and cannabinoid CB2 receptors at the central nervous system (CNS) level. In a heterologous system we identified CB2-GHSR1a receptor complexes with a particular heteromer print consisting of impairment of CB2 receptor/Gi-mediated signaling. The blockade was due to allosteric interactions within the heteromeric complex as it was reverted by antagonists of the GHSR1a receptor. Cannabinoids acting on the CB2 receptor did not affect cytosolic increases of calcium ions induced by ghrelin acting on the GHSR1a receptor. In situ proximity ligation imaging assays confirmed the expression of CB2-GHSR1a receptor complexes in both heterologous cells and primary striatal neurons. We tested heteromer expression in neurons from offspring of high-fat-diet mouse mothers as they have more risk to be obese. Interestingly, there was a marked upregulation of those complexes in striatal neurons from siblings of pregnant female mice under a high-fat diet.

[1]  K. Mackie,et al.  Cannabinoid Receptor Modulation of Neurogenesis: ST14A Striatal Neural Progenitor Cells as a Simplified In Vitro Model , 2021, Molecules.

[2]  L. Pardo,et al.  Discovery of a macromolecular complex mediating the hunger suppressive actions of cocaine: Structural and functional properties , 2021, Addiction biology.

[3]  Anne-Caroline Schmöle,et al.  CB2 Receptor in Microglia: The Guardian of Self-Control , 2020, International journal of molecular sciences.

[4]  R. Franco,et al.  Biological potential of varinic-, minor-, and acidic phytocannabinoids. , 2020, Pharmacological research.

[5]  R. Capasso,et al.  Terpenoids, Cannabimimetic Ligands, beyond the Cannabis Plant , 2020, Molecules.

[6]  B. Vissel,et al.  Targeting the cannabinoid receptor CB2 in a mouse model of l-dopa induced dyskinesia , 2020, Neurobiology of Disease.

[7]  Liming Cheng,et al.  Activation of CB2R with AM1241 ameliorates neurodegeneration via the Xist/miR‐133b‐3p/Pitx3 axis , 2020, Journal of cellular physiology.

[8]  Arthur Christopoulos,et al.  THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein‐coupled receptors , 2019, British journal of pharmacology.

[9]  R. Franco,et al.  Increased expression of cannabinoid CB2 and serotonin 5-HT1A heteroreceptor complexes in a model of newborn hypoxic-ischemic brain damage , 2019, Neuropharmacology.

[10]  N. Heslehurst,et al.  The association between maternal body mass index and child obesity: A systematic review and meta-analysis , 2019, PLoS medicine.

[11]  Í. Azcoitia,et al.  The endocannabinoid 2-AG enhances spontaneous remyelination by targeting microglia , 2019, Brain, Behavior, and Immunity.

[12]  R. Franco,et al.  Biased receptor functionality versus biased agonism in G-protein-coupled receptors , 2018, Biomolecular concepts.

[13]  R. Franco,et al.  Cannabidiol skews biased agonism at cannabinoid CB1 and CB2 receptors with smaller effect in CB1‐CB2 heteroreceptor complexes , 2018, Biochemical pharmacology.

[14]  A. Howlett,et al.  The Endocannabinoid System and Oligodendrocytes in Health and Disease , 2018, Front. Neurosci..

[15]  M. Colonna,et al.  The identity and function of microglia in neurodegeneration , 2018, Nature Immunology.

[16]  C. Müller,et al.  Molecular and functional interaction between GPR18 and cannabinoid CB2 G‐protein‐coupled receptors. Relevance in neurodegenerative diseases , 2018, Biochemical pharmacology.

[17]  J. Mallol,et al.  Orexin A/Hypocretin Modulates Leptin Receptor-Mediated Signaling by Allosteric Modulations Mediated by the Ghrelin GHS-R1A Receptor in Hypothalamic Neurons , 2018, Molecular Neurobiology.

[18]  L. Pardo,et al.  Cross-communication between Gi and Gs in a G-protein-coupled receptor heterotetramer guided by a receptor C-terminal domain , 2018, BMC Biology.

[19]  J. Lanciego,et al.  Alterations in Gene and Protein Expression of Cannabinoid CB2 and GPR55 Receptors in the Dorsolateral Prefrontal Cortex of Suicide Victims , 2018, Neurotherapeutics.

[20]  S. Ametamey,et al.  Evaluation of 4-oxo-quinoline-based CB2 PET radioligands in R6/2 chorea huntington mouse model and human ALS spinal cord tissue. , 2018, European journal of medicinal chemistry.

[21]  K. Fuxe,et al.  Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB1 and CB2 receptors and relevance for Alzheimer’s disease and levodopa-induced dyskinesia , 2018, Brain, Behavior, and Immunity.

[22]  Julen Oyarzabal,et al.  Binding and Signaling Studies Disclose a Potential Allosteric Site for Cannabidiol in Cannabinoid CB2 Receptors , 2017, Front. Pharmacol..

[23]  Ryan M. Cassidy,et al.  Hunger and Satiety Gauge Reward Sensitivity , 2017, Front. Endocrinol..

[24]  C. Vargas,et al.  Cannabidiol reduces brain damage and improves functional recovery in a neonatal rat model of arterial ischemic stroke , 2017, Neuropharmacology.

[25]  G. Muccioli,et al.  Obesity-Induced Neuroinflammation: Beyond the Hypothalamus , 2017, Trends in Neurosciences.

[26]  M. Delgado,et al.  Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington’s Disease , 2017, International journal of molecular sciences.

[27]  X. Montalban,et al.  Gut dysbiosis and neuroimmune responses to brain infection with Theiler’s murine encephalomyelitis virus , 2017, Scientific Reports.

[28]  A. Romano,et al.  Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target , 2017, Front. Neurosci..

[29]  J. Martínez-Orgado,et al.  Neuroprotective Effects of Cannabidiol in Hypoxic Ischemic Insult. The Therapeutic Window in Newborn Mice. , 2017, CNS & neurological disorders drug targets.

[30]  E. Mazzon,et al.  Cannabidiol Modulates the Expression of Alzheimer’s Disease-Related Genes in Mesenchymal Stem Cells , 2016, International journal of molecular sciences.

[31]  L. Mestre,et al.  Microglia activation states and cannabinoid system: Therapeutic implications. , 2016, Pharmacology & therapeutics.

[32]  R. Franco,et al.  Targeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative Disorders , 2016, Front. Neurosci..

[33]  J. Fernández-Ruiz,et al.  Targeting cannabinoid CB2 receptors in the Central Nervous System. Medicinal chemistry approaches and focus on neurodegenerative disorders affecting movement , 2016 .

[34]  J. Fernández-Ruiz,et al.  Targeting the cannabinoid CB2 receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice. , 2016, Pharmacological research.

[35]  J. Martínez-Orgado,et al.  Short-term effects of cannabidiol after global hypoxia-ischemia in newborn piglets , 2016, Pediatric Research.

[36]  J. Fernández-Ruiz,et al.  Cannabinoid–dopamine interactions in the physiology and physiopathology of the basal ganglia , 2016, British journal of pharmacology.

[37]  C. Carroll,et al.  Delta-9-tetrahydrocannabinol protects against MPP+ toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis , 2016, Oncotarget.

[38]  L. Pardo,et al.  Quaternary structure of a G-protein-coupled receptor heterotetramer in complex with Gi and Gs , 2016, BMC Biology.

[39]  J. Lanciego,et al.  Basic Pharmacological and Structural Evidence for Class A G-Protein-Coupled Receptor Heteromerization , 2016, Front. Pharmacol..

[40]  J. Fernández-Ruiz,et al.  Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson's disease , 2016, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[41]  Ainoa Rueda-Zubiaurre,et al.  Endocannabinoids drive the acquisition of an alternative phenotype in microglia , 2015, Brain, Behavior, and Immunity.

[42]  J. Argente,et al.  Role of Non-Neuronal Cells in Body Weight and Appetite Control , 2015, Front. Endocrinol..

[43]  S. Spencer,et al.  Named Series : Diet , Inflammation and the Brain Obesity and neuroinflammation : A pathway to cognitive impairment , 2014 .

[44]  D. Fair,et al.  Dietary intervention rescues maternal obesity induced behavior deficits and neuroinflammation in offspring , 2014, Journal of Neuroinflammation.

[45]  J. Lanciego,et al.  Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism , 2014, Brain Structure and Function.

[46]  K. Fuxe,et al.  The G Protein-Coupled Receptor Heterodimer Network (GPCR-HetNet) and Its Hub Components , 2014, International journal of molecular sciences.

[47]  R. Mechoulam,et al.  Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors , 2013, Neuropharmacology.

[48]  E. Pinteaux,et al.  Neuroimmmune interactions of cannabinoids in neurogenesis: focus on interleukin-1β (IL-1β) signalling. , 2013, Biochemical Society transactions.

[49]  S. Samson,et al.  Ghrelin: much more than a hunger hormone , 2013, Current opinion in clinical nutrition and metabolic care.

[50]  M. Kreutz,et al.  NCS-1 associates with adenosine A2A receptors and modulates receptor function , 2012, Front. Mol. Neurosci..

[51]  J. Martínez-Orgado,et al.  Cannabidiol Reduces Brain Damage and Improves Functional Recovery After Acute Hypoxia-Ischemia in Newborn Pigs , 2011, Pediatric Research.

[52]  M. Ghatei,et al.  Rimonabant: From RIO to Ban , 2011, Journal of obesity.

[53]  J. Lanciego,et al.  Expression of the mRNA coding the cannabinoid receptor 2 in the pallidal complex of Macaca fascicularis , 2011, Journal of psychopharmacology.

[54]  Miguel Martín,et al.  Deficiency of CB2 cannabinoid receptor in mice improves insulin sensitivity but increases food intake and obesity with age , 2010, Diabetologia.

[55]  T. Dinan,et al.  Lean mean fat reducing “ghrelin” machine: Hypothalamic ghrelin and ghrelin receptors as therapeutic targets in obesity , 2010, Neuropharmacology.

[56]  Michel Bouvier,et al.  Building a new conceptual framework for receptor heteromers. , 2009, Nature chemical biology.

[57]  T. Horvath,et al.  Brain circuits regulating energy homeostasis , 2008, Regulatory Peptides.

[58]  Gemma Navarro,et al.  Detection of heteromerization of more than two proteins by sequential BRET-FRET , 2008, Nature Methods.

[59]  Niveen M. E. Abu-Rmeileh,et al.  Contribution of Midparental BMI and Other Determinants of Obesity in Adult Offspring , 2008, Obesity.

[60]  P. Sexton,et al.  Pattern of Intra-Family Hetero-Oligomerization Involving the G-Protein-Coupled Secretin Receptor , 2008, Journal of Molecular Neuroscience.

[61]  L. Mestre,et al.  Therapeutic potential of CB2 targeting in multiple sclerosis , 2008 .

[62]  A. Astrup,et al.  [A meta-analysis of the efficacy and safety of the anti-obesity agent Rimonabant]. , 2007, Ugeskrift for laeger.

[63]  J. Borrell,et al.  Cannabinoid System and Neuroinflammation: Implications for Multiple Sclerosis , 2007, Neuroimmunomodulation.

[64]  J. Fernández-Ruiz,et al.  Cannabinoids and neuroprotection in motor-related disorders. , 2007, CNS & neurological disorders drug targets.

[65]  Robin Christensen,et al.  Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials , 2007, The Lancet.

[66]  M. García-Arencibia,et al.  Cannabinoids and Neuroprotection in Basal Ganglia Disorders , 2007, Molecular Neurobiology.

[67]  M. Korbonits,et al.  Ghrelin, the peripheral hunger hormone , 2007, Annals of medicine.

[68]  G. Gessa,et al.  Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data. , 2006, CNS drug reviews.

[69]  Jean Martinez,et al.  Regulation of ERK1/2 activity by ghrelin‐activated growth hormone secretagogue receptor 1A involves a PLC/PKCɛ pathway , 2006 .

[70]  G. Marsicano,et al.  How many sites of action for endocannabinoids to control energy metabolism? , 2006, International Journal of Obesity.

[71]  V. Darras,et al.  Distribution and regulation of chicken growth hormone secretagogue receptor isoforms. , 2003, General and comparative endocrinology.

[72]  S. Shioda,et al.  Hypothalamic neuronal networks and feeding-related peptides involved in the regulation of feeding , 2003, Anatomical science international.

[73]  J. Borrell,et al.  Cannabinoids Promote Oligodendrocyte Progenitor Survival: Involvement of Cannabinoid Receptors and Phosphatidylinositol-3 Kinase/Akt Signaling , 2002, The Journal of Neuroscience.

[74]  Roy G. Smith,et al.  Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues. , 1997, Brain research. Molecular brain research.

[75]  T. Morera-Herreras,et al.  Therapeutic potential of cannabinoids as neuroprotective agents for damaged cells conducing to movement disorders. , 2019, International review of neurobiology.

[76]  J. Ramos,et al.  Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others. , 2015, Handbook of experimental pharmacology.